Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Sticks to Its Buy Rating for Avid Bioservices (CDMO)
RBC Capital Downgrades Avid Bioservices(CDMO.US) to Hold Rating, Raises Target Price to $12.5
Avid Bioservices Analyst Ratings
Stephens & Co. Reiterates Overweight on Avid Bioservices, Maintains $12 Price Target
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating, Announces Target Price $16
RBC Capital Maintains Avid Bioservices(CDMO.US) With Buy Rating, Raises Target Price to $12
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Initiates Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
RBC Capital Reiterates Outperform on Avid Bioservices, Maintains $8 Price Target
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices (CDMO) Receives a Buy From Craig-Hallum
Craig-Hallum Sticks to Their Buy Rating for Avid Bioservices (CDMO)
Royal Bank of Canada: Maintaining the Avid Bioservices (CDMO.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $7.00 to $8.00.
No Data
No Data